Literature DB >> 16339909

Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection.

Simon D W Frost1, Terri Wrin, Davey M Smith, Sergei L Kosakovsky Pond, Yang Liu, Ellen Paxinos, Colombe Chappey, Justin Galovich, Jeff Beauchaine, Christos J Petropoulos, Susan J Little, Douglas D Richman.   

Abstract

HIV type 1 (HIV-1) can rapidly escape from neutralizing antibody responses. The genetic basis of this escape in vivo is poorly understood. We compared the pattern of evolution of the HIV-1 env gene between individuals with recent HIV infection whose virus exhibited either a low or a high rate of escape from neutralizing antibody responses. We demonstrate that the rate of viral escape at a phenotypic level is highly variable among individuals, and is strongly correlated with the rate of amino acid substitutions. We show that dramatic escape from neutralizing antibodies can occur in the relative absence of changes in glycosylation or insertions and deletions ("indels") in the envelope; conversely, changes in glycosylation and indels occur even in the absence of neutralizing antibody responses. Comparison of our data with the predictions of a mathematical model support a mechanism in which escape from neutralizing antibodies occurs via many amino acid substitutions, with low cross-neutralization between closely related viral strains. Our results suggest that autologous neutralizing antibody responses may play a pivotal role in the diversification of HIV-1 envelope during the early stages of infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16339909      PMCID: PMC1310509          DOI: 10.1073/pnas.0504658102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  63 in total

1.  Selection in context: patterns of natural selection in the glycoprotein 120 region of human immunodeficiency virus 1 within infected individuals.

Authors:  Alan R Templeton; Rebecca A Reichert; Anton E Weisstein; Xiao-Fang Yu; Richard B Markham
Journal:  Genetics       Date:  2004-08       Impact factor: 4.562

2.  Convergent and divergent sequence evolution in the surface envelope glycoprotein of human immunodeficiency virus type 1 within a single infected patient.

Authors:  E C Holmes; L Q Zhang; P Simmonds; C A Ludlam; A J Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

3.  Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions.

Authors:  M Nei; T Gojobori
Journal:  Mol Biol Evol       Date:  1986-09       Impact factor: 16.240

Review 4.  Glycoproteins.

Authors:  R D Marshall
Journal:  Annu Rev Biochem       Date:  1972       Impact factor: 23.643

5.  Identification of common molecular subsequences.

Authors:  T F Smith; M S Waterman
Journal:  J Mol Biol       Date:  1981-03-25       Impact factor: 5.469

6.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule.

Authors:  R A Fouchier; M Groenink; N A Kootstra; M Tersmette; H G Huisman; F Miedema; H Schuitemaker
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

7.  Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis.

Authors:  P Simmonds; L Q Zhang; F McOmish; P Balfe; C A Ludlam; A J Brown
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

8.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.

Authors:  J Albert; B Abrahamsson; K Nagy; E Aurelius; H Gaines; G Nyström; E M Fenyö
Journal:  AIDS       Date:  1990-02       Impact factor: 4.177

9.  Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads.

Authors:  I Pellegrin; E Legrand; D Neau; P Bonot; B Masquelier; J L Pellegrin; J M Ragnaud; N Bernard; H J Fleury
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-04-15

10.  Analysis of the V3 loop in neutralization-resistant human immunodeficiency virus type 1 variants by direct solid-phase DNA sequencing.

Authors:  J Wahlberg; J Albert; J Lundeberg; A Von Gegerfelt; K Broliden; G Utter; E M Fenyö; M Uhlén
Journal:  AIDS Res Hum Retroviruses       Date:  1991-12       Impact factor: 2.205

View more
  189 in total

1.  HIV-1 continues to replicate and evolve in patients with natural control of HIV infection.

Authors:  Helene Mens; Mary Kearney; Ann Wiegand; Wei Shao; Kristian Schønning; Jan Gerstoft; Niels Obel; Frank Maldarelli; John W Mellors; Thomas Benfield; John M Coffin
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV.

Authors:  Mark D Hicar; Xuemin Chen; Bryan Briney; Jason Hammonds; Jaang-Jiun Wang; Spyros Kalams; Paul W Spearman; James E Crowe
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

3.  Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1.

Authors:  Gülsen Ozkaya Sahin; Birgitta Holmgren; Zacarias da Silva; Jens Nielsen; Salma Nowroozalizadeh; Joakim Esbjörnsson; Fredrik Månsson; Sören Andersson; Hans Norrgren; Peter Aaby; Marianne Jansson; Eva Maria Fenyö
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

4.  A versatile vector for the production of pseudotyped viruses expressing gp120 antigens from different clades of primary HIV-1 isolates.

Authors:  Zheng Wang; Mingshun Zhang; Yan Wang; Yanmei Jiao; Lu Zhang; Lin Li; Zuhu Huang; Hao Wu; Jingyun Li; Shan Lu; Shixia Wang
Journal:  J Virol Methods       Date:  2010-10-27       Impact factor: 2.014

5.  Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization.

Authors:  James M Binley; Yih-En Andrew Ban; Emma T Crooks; Dirk Eggink; Keiko Osawa; William R Schief; Rogier W Sanders
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

Review 6.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

7.  Evolution of HIV-1 coreceptor usage and coreceptor switching during pregnancy.

Authors:  Doris G Ransy; Alena Motorina; Natacha Merindol; Bertine S Akouamba; Johanne Samson; Yolanda Lie; Laura A Napolitano; Normand Lapointe; Marc Boucher; Hugo Soudeyns
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-25       Impact factor: 2.205

8.  High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.

Authors:  Katie L Davis; Elin S Gray; Penny L Moore; Julie M Decker; Aidy Salomon; David C Montefiori; Barney S Graham; Michael C Keefer; Abraham Pinter; Lynn Morris; Beatrice H Hahn; George M Shaw
Journal:  Virology       Date:  2009-03-18       Impact factor: 3.616

9.  Design requirements for interfering particles to maintain coadaptive stability with HIV-1.

Authors:  Igor M Rouzine; Leor S Weinberger
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

10.  Selection of HIV variants with signature genotypic characteristics during heterosexual transmission.

Authors:  Manish Sagar; Oliver Laeyendecker; Sandra Lee; Jordyn Gamiel; Maria J Wawer; Ronald H Gray; David Serwadda; Nelson K Sewankambo; James C Shepherd; Jonathan Toma; Wei Huang; Thomas C Quinn
Journal:  J Infect Dis       Date:  2009-02-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.